Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VRAX | US
0.10
6.54%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.63
1.51
1.69
1.50
Virax Biolabs Group Limited a biotechnology company sells distributes and markets diagnostics test kits for the prevention detection diagnosis and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests antigen tests polymerase chain reaction rapid tests and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19 which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics pharmacies laboratories hospitals and other groups as well as corporations pharmaceutical companies research institutions hospital systems and public and private institutions. The company operates in Europe South America the Asia Pacific Sub-Saharan Africa and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London the United Kingdom.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
73.5%1 month
112.1%3 months
373.8%6 months
300.4%-
-
1.24
0.04
0.04
0.42
20.96
-
-6.05M
7.08M
7.08M
-
-4.25K
-
2.75K
-95.98
0.16
6.30
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.47
Range1M
1.05
Range3M
8.05
Rel. volume
0.71
Price X volume
403.22K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.73 | 7.74M | 3.28% | n/a | 0.00% |
Moleculin Biotech Inc | MBRX | Biotechnology | 2.67 | 7.59M | 3.29% | n/a | 3.00% |
Pulmatrix Inc | PULM | Biotechnology | 2.04 | 7.45M | 0.97% | n/a | 0.18% |
Cyclerion Therapeutics Inc | CYCN | Biotechnology | 2.9099 | 7.32M | 16.40% | n/a | 0.00% |
Orgenesis Inc | ORGS | Biotechnology | 1.53 | 7.30M | -27.49% | n/a | -84.02% |
Purple Biotech Ltd | PPBT | Biotechnology | 4.49 | 7.07M | 2.75% | n/a | 0.89% |
CDIO | CDIO | Biotechnology | 0.231 | 7.07M | 9.53% | n/a | 28.31% |
Galmed Pharmaceuticals Ltd | GLMD | Biotechnology | 4.68 | 7.05M | 23.16% | n/a | 0.00% |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.69 | 6.99M | 6.32% | n/a | -4.26% |
Aptose Biosciences Inc | APTO | Biotechnology | 0.3889 | 6.96M | 6.75% | n/a | -37.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.42 | 0.53 | Cheaper |
Ent. to Revenue | 20.96 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 1.24 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 373.78 | 72.80 | Riskier |
Debt to Equity | 0.04 | -1.23 | Expensive |
Debt to Assets | 0.04 | 0.25 | Cheaper |
Market Cap | 7.08M | 3.66B | Emerging |